Long Non-Coding RNAs in Diffuse Large B-Cell Lymphoma

Karstensen, Kasper Thystrup; Schein, Aleks; Petri, Andreas; Bøgsted, Martin; Dybkær, Karen; Uchida, Shizuka; Kauppinen, Sakari

doi:10.3390/ncrna7010001

Cited by 8 publications

(6 citation statements)

References 113 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the IPI systems do not consider factors inherent to the molecular heterogeneity of patients, leading to the critical need of identifying additional molecular prognostic biomarkers. In the last decade, several studies have demonstrated the contribution of miRNAs to lymphoma development, implying their potential as novel biomarkers in cancer diagnosis and prognosis [ 14 ]. More recently, a new class of ncRNA, the lncRNAs, has emerged also as important regulators of gene expression, and their deregulation has been implicated in the initiation and progression of cancer, showing great potential as predictive biomarkers.…”

Section: Discussionmentioning

confidence: 99%

“…The expression levels of hsa-hsa-miR-27a, hsa-hsa-miR-142, hsa-miR-199b, hsa-miR-222, hsa-miR-302, hsa-miR-330, hsa-miR-425, and hsa-miR-519 seemed to be associated with OS of R-CHOP treated patients with DLBCL [ 13 ]. Recently, lncRNAs have emerged as a new level of gene expression regulation, playing an important role in lymphoma development [ 14 ]. LncRNAs are >200 nt long transcripts with no protein-coding capacity [ 15 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

ceRNA Network of lncRNA/miRNA as Circulating Prognostic Biomarkers in Non-Hodgkin Lymphomas: Bioinformatic Analysis and Assessment of Their Prognostic Value in an NHL Cohort

Fernandes

Marques

Teixeira

et al. 2021

IJMS

View full text Add to dashboard Cite

Research has been focusing on identifying novel biomarkers to better stratify non-Hodgkin lymphoma patients based on prognosis. Studies have demonstrated that lncRNAs act as miRNA sponges, creating ceRNA networks to regulate mRNA expression, and its deregulation is associated with lymphoma development. This study aimed to identify novel circulating prognostic biomarkers based on miRNA/lncRNA-associated ceRNA network for NHL. Herein, bioinformatic analysis was performed to construct ceRNA networks for hsa-miR-150-5p and hsa-miR335-5p. Then, the prognostic value of the miRNA–lncRNA pairs’ plasma levels was assessed in a cohort of 113 NHL patients. Bioinformatic analysis identified MALAT1 and NEAT1 as hsa-miR-150-5p and has-miR-335-5p sponges, respectively. Plasma hsa-miR-150-5p/MALAT1 and hsa-miR335-5p/NEAT1 levels were significantly associated with more aggressive and advanced disease. The overall survival and progression-free survival analysis indicated that hsa-miR-150-5p/MALAT1 and hsa-miR335-5p/NEAT1 pairs’ plasma levels were remarkably associated with NHL patients’ prognosis, being independent prognostic factors in a multivariate Cox analysis. Low levels of hsa-miR-150-5p and hsa-miR-335-5p combined with high levels of the respective lncRNA pair were associated with poor prognosis of NHL patients. Overall, the analysis of ceRNA network expression levels may be a useful prognostic biomarker for NHL patients and could identify patients who could benefit from more intensive treatments.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

ceRNA Network of lncRNA/miRNA as Circulating Prognostic Biomarkers in Non-Hodgkin Lymphomas: Bioinformatic Analysis and Assessment of Their Prognostic Value in an NHL Cohort

Fernandes

Marques

Teixeira

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…Using RNA sequencing, Karstensen et al analyzed the transcription profile of rituximab-sensitive and resistant DLBCL cell lines. They observed a differential expression of lncRNA between sensitive and resistant cells, comprising 54 up and 69 downregulated lncRNAs [ 154 ]. In MCL cells, a study by Mourtada-Maarabouni et al demonstrated that lncRNA GAS5 regulates the effect of known mTOR inhibitors, such as rapamycin, everolimus, and temsirolimus.…”

Section: Mirnas and Lncrnas As Potential Biomarkers For Nhlmentioning

confidence: 99%

Competitive Endogenous RNA Network Involving miRNA and lncRNA in Non-Hodgkin Lymphoma: Current Advances and Clinical Perspectives

et al. 2021

View full text Add to dashboard Cite

Non-Hodgkin lymphoma (NHL) is a heterogeneous malignancy with variable patient outcomes. There is still a lack of understanding about the different players involved in lymphomagenesis, and the identification of new diagnostic and prognostic biomarkers is urgent. MicroRNAs and long non-coding RNAs emerged as master regulators of B-cell development, and their deregulation has been associated with the initiation and progression of lymphomagenesis. They can function by acting alone or, as recently proposed, by creating competing endogenous RNA (ceRNA) networks. Most studies have focused on individual miRNAs/lncRNAs function in lymphoma, and there is still limited data regarding their interactions in lymphoma progression. The study of miRNAs’ and lncRNAs’ deregulation in NHL, either alone or as ceRNAs networks, offers new insights into the molecular mechanisms underlying lymphoma pathogenesis and opens a window of opportunity to identify potential diagnostic and prognostic biomarkers. In this review, we summarized the current knowledge regarding the role of miRNAs and lncRNAs in B-cell lymphoma, including their interactions and regulatory networks. Finally, we summarized the studies investigating the potential of miRNAs and lncRNAs as clinical biomarkers, with a special focus on the circulating profiles, to be applied as a non-invasive, easy-to-obtain, and reproducible liquid biopsy for dynamic management of NHL patients.

show abstract

“…Long non-coding RNA also plays a vital role in the occurrence, progression, resistance, and prognosis of DLBCL [21][22][23] . LINC00857 can promote the occurrence and progression of DLBCL 24 .…”

Section: Introductionmentioning

confidence: 99%

lncRNA CHROMR promotes the expression of the CNNM1 gene by adsorbing hsa-miR-1299 to obtain drug resistance in diffuse large B lymphoma cells

Wei

Wang

Miao

2022

Preprint

View full text Add to dashboard Cite

Background: Long-chain non-coding RNA (LncRNA) is differentially expressed in diffuse large B cell lines with varying degrees of resistance to rituximab, which plays a regulatory role in the cell cycle, and has a cancer-promoting effect. Methods: This study investigated the role of lncRNA CHROMR in the diffuse large B lymphoma cells producing rituximab resistance and explored its underlying mechanism. We searched the GEO database for lncRNA-related expression data of rituximab resistance in the diffuse large B lymphoma cell line and tested it in cell lines. It was found that CHROMR was differentially expressed in different types of samples, and then the effect of CHROMR in the acquisition of drug resistance of cells was verified through experiments such as cell cycle, cell apoptosis, and cell proliferation. We use bioinformatics analysis to predict that there may be a CHROMR/miR-1299/CNNM1 signaling pathway that enables the diffuse large B lymphoma cells to acquire drug resistance. We first use dual-luciferase analysis to verify the interaction between pathway molecules. We use bioinformatics analysis to predict that there may be a CHROMR/miR-1299/CNNM1 signaling pathway that enables the diffuse large B lymphoma cells to acquire drug resistance. We first use dual-luciferase analysis to verify the interaction between pathway molecules. The cells were co-transfected with or without sh-CHROMR and miR-1299 inhibitor, CHROMR -over and miR-1299 mimic, whose proliferation, apoptosis, and cell cycle were determined subsequently. Results: The results show that restoring the expression of miR-1299 can offset the effects of changes in CHROMR expression. Conclusions: CHROMR promotes the expression of CNNM1 by adsorbing miR-1299 to cause changes in the cell cycle of the diffuse large B lymphoma cells to produce drug resistance.

show abstract

Long Non-Coding RNAs in Diffuse Large B-Cell Lymphoma

Cited by 8 publications

References 113 publications

ceRNA Network of lncRNA/miRNA as Circulating Prognostic Biomarkers in Non-Hodgkin Lymphomas: Bioinformatic Analysis and Assessment of Their Prognostic Value in an NHL Cohort

ceRNA Network of lncRNA/miRNA as Circulating Prognostic Biomarkers in Non-Hodgkin Lymphomas: Bioinformatic Analysis and Assessment of Their Prognostic Value in an NHL Cohort

Competitive Endogenous RNA Network Involving miRNA and lncRNA in Non-Hodgkin Lymphoma: Current Advances and Clinical Perspectives

lncRNA CHROMR promotes the expression of the CNNM1 gene by adsorbing hsa-miR-1299 to obtain drug resistance in diffuse large B lymphoma cells

Contact Info

Product

Resources

About